BioCryst director granted 644 shares in lieu of cash

BCRX director Amy E. McKee took part of her quarterly board retainer in stock, modestly increasing her direct share ownership.

Rhea-AI Filing Summary

BIOCRYST PHARMACEUTICALS INC (symbol: BCRX) is the issuer of record for a Form 4 filing submitted to the SEC. McKee Amy E reported acquisition or exercise transactions in this Form 4 filing.

BIOCRYST PHARMACEUTICALS INC (BCRX) director Amy E. McKee received a grant of 644 shares of Common Stock on August 31, 2026, valued at $9.70 per share. The shares were issued in lieu of 50% of her $12,500 quarterly Board member cash retainer, bringing her direct holdings to 47,821 shares. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Grant/Award: 644 shares

Grant/Award 1 txn

Insider McKee Amy E

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	644	$9.70	$6K

Holdings After Transaction: Common Stock — 47,821 shares (Direct)

Footnotes (1)

1. F1. Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $12,500.

Key Figures

Shares granted: 644 shares Grant price per share: $9.70 per share Quarterly Board member retainer: $12,500 +2 more

5 metrics

Shares granted 644 shares Director stock grant on August 31, 2026 in lieu of cash retainer

Grant price per share $9.70 per share Value assigned to the 644-share Common Stock grant

Quarterly Board member retainer $12,500 Cash Board member retainer, 50% taken in stock for this grant

Shares owned after transaction 47,821 shares Direct Common Stock holdings of Amy E. McKee after the grant

Value of stock portion of retainer $6,250 Portion of the $12,500 quarterly retainer taken as 644 shares

Key Terms

Common Stock, quarterly cash Board Member retainer, Rule 10b5-1

3 terms

Common Stock financial

"Shares of Common Stock issued to the reporting person in lieu of 50%"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

quarterly cash Board Member retainer financial

"in lieu of 50% of the quarterly cash Board Member retainer of $12,500"

Rule 10b5-1 regulatory

"No Rule 10b5-1 trading plan is reported for this transaction"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BCRX director Amy E. McKee report on this Form 4?

Amy E. McKee reported a grant of 644 shares of Common Stock of BioCryst Pharmaceuticals on August 31, 2026, received as part of her director compensation rather than a cash payment.

What was the value of the BCRX shares granted to Amy E. McKee?

The 644 BioCryst shares were valued at $9.70 per share, corresponding to $6,250, which equals 50% of her $12,500 quarterly Board member cash retainer that was taken in stock.

How many BCRX shares does Amy E. McKee own after this transaction?

Following the August 31, 2026 grant, Amy E. McKee directly owns 47,821 shares of BioCryst Pharmaceuticals Common Stock, as reported in the filing.

Was this BCRX Form 4 transaction part of a Rule 10b5-1 plan?

No. The filing indicates that no Rule 10b5-1 trading plan is reported for this transaction; it reflects a director compensation grant rather than an open-market trade.

Did Amy E. McKee buy or sell BCRX shares on the market in this filing?

No market purchase or sale is reported. The Form 4 shows an acquisition by grant of 644 shares of Common Stock as director compensation, with no shares sold in this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 04:08 PM EDT Accepted by SEC EDGAR 09/02/2026 - 04:06 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McKee Amy E

(Last) (First) (Middle)

4505 EMPEROR BLVD.

SUITE 200

(Street)

DURHAM NORTH CAROLINA 27703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/31/2026		A		644(1)	A	$9.7	47,821	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $12,500.

	/s/ Alane P. Barnes, by power of attorney	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)